{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:36:37Z","timestamp":1787841397473,"version":"build-2784847793"},"reference-count":26,"publisher":"Japanese Society of Veterinary Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Vet. Med. Sci.","The Journal of Veterinary Medical Science"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1292\/jvms.20-0352","type":"journal-article","created":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T22:08:16Z","timestamp":1638742096000},"page":"142-148","source":"Crossref","is-referenced-by-count":4,"title":["A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine"],"prefix":"10.1292","volume":"84","author":[{"given":"Masaharu","family":"HISASUE","sequence":"first","affiliation":[{"name":"Laboratory of Small Animal Internal Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"TANAKA","sequence":"additional","affiliation":[{"name":"Azabu University Veterinary Teaching Hospital, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan"},{"name":"Shoko Animal Hospital, 407-8 Shinzen-cho, Soka, Saitama 340-0054, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakurako","family":"NEO","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Diagnosis, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Akiyama, N., Miyazawa, K., Kanda, Y., Tohyama, K., Omine, M., Mitani, K. and Ohyashiki, K. 2010. Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1alpha-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes. <i>Leuk. Res.<\/i> 34: 1151\u20131157.","DOI":"10.1016\/j.leukres.2010.04.006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Breuer, W., Hermanns, W. and Thiele, J. 1999. Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and chronic myeloproliferative disorder (CMPD) in cats. <i>J. Comp. Pathol.<\/i> 121: 203\u2013216.","DOI":"10.1053\/jcpa.1999.0314"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ettinger, S. N. 2003. Principles of treatment for feline lymphoma. <i>Clin. Tech. Small Anim. Pract.<\/i> 18: 98\u2013102.","DOI":"10.1053\/svms.2003.36623"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fischer, C., Tan, E. and Bienzle, D. 2012. Erythroleukemia in a retrovirus-negative cat. <i>J. Am. Vet. Med. Assoc.<\/i> 240: 294\u2013297.","DOI":"10.2460\/javma.240.3.294"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fujita, M. and Kaneda, M. 2017. DNA methylation inhibitor causes cell growth retardation and gene expression changes in feline lymphoma cells. <i>J. Vet. Med. Sci.<\/i> 79: 1352\u20131358.","DOI":"10.1292\/jvms.17-0179"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hahn, N. M., Bonney, P. L., Dhawan, D., Jones, D. R., Balch, C., Guo, Z., Hartman-Frey, C., Fang, F., Parker, H. G., Kwon, E. M., Ostrander, E. A., Nephew, K. P. and Knapp, D. W. 2012. Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. <i>J. Urol.<\/i> 187: 302\u2013309.","DOI":"10.1016\/j.juro.2011.09.010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Harman, R. M., Curtis, T. M., Argyle, D. J., Coonrod, S. A. and Van de Walle, G. R. 2016. A comparative study on the in vitro effects of the DNA methyltransferase inhibitor 5-azacytidine (5-AzaC) in breast\/mammary cancer of different mammalian species. <i>J. Mammary Gland Biol. Neoplasia<\/i> 21: 51\u201366.","DOI":"10.1007\/s10911-016-9350-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hisasue, M., Okayama, H., Okayama, T., Suzuki, T., Mizuno, T., Fujino, Y., Naganobu, K., Hasegawa, A., Watari, T., Matsuki, N., Masuda, K., Ohno, K. and Tsujimoto, H. 2001. Hematologic abnormalities and outcome of 16 cats with myelodysplastic syndromes. <i>J. Vet. Intern. Med.<\/i> 15: 471\u2013477.","DOI":"10.1111\/j.1939-1676.2001.tb01577.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hisasue, M., Nishigaki, K., Katae, H., Yuri, K., Mizuno, T., Fujino, Y., Setoguchi, A., Hasegawa, A., Watari, T., Masuda, K., Ohno, K. and Tsujimoto, H. 2000. Clonality analysis of various hematopoietic disorders in cats naturally infected with feline leukemia virus. <i>J. Vet. Med. Sci.<\/i> 62: 1059\u20131065.","DOI":"10.1292\/jvms.62.1059"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hisasue, M., Nagashima, N., Nishigaki, K., Fukuzawa, I., Ura, S., Katae, H., Tsuchiya, R., Yamada, T., Hasegawa, A. and Tsujimoto, H. 2009. Myelodysplastic syndromes and acute myeloid leukemia in cats infected with feline leukemia virus clone33 containing a unique long terminal repeat. <i>Int. J. Cancer<\/i> 124: 1133\u20131141.","DOI":"10.1002\/ijc.24050"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jain, N. C., Blue, J. T., Grindem, C. B., Harvey, J. W., Kociba, G. J., Krehbiel, J. D., Latimer, K. S., Raskin, R. E., Thrall, M. A. and Zinkl, J. G. 1991. Proposed criteria for classification of acute myeloid leukemia in dogs and cats. <i>Vet. Clin. Pathol.<\/i> 20: 63\u201382.","DOI":"10.1111\/j.1939-165X.1991.tb00571.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kubasch, A. S. and Platzbecker, U. 2018. Beyond the edge of hypomethylating agents: novel combination strategies for older adults with advanced MDS and AML. <i>Cancers (Basel)<\/i> 10: E158.","DOI":"10.3390\/cancers10060158"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Montoro, J., Yerlikaya, A., Ali, A. and Raza, A. 2018. Improving treatment for myelodysplastic syndromes patients. <i>Curr. Treat. Options Oncol.<\/i> 19: 66.","DOI":"10.1007\/s11864-018-0583-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. M\u00fcller, A. M. and Florek, M. 2014. 5-azacytidine\/5-azacitidine. <i>Recent Results Cancer Res.<\/i> 201: 299\u2013324.","DOI":"10.1007\/978-3-642-54490-3_19"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nagashima, N., Hisasue, M., Nishigaki, K., Miyazawa, T., Kano, R. and Hasegawa, A. 2005. In vitro selective suppression of feline myeloid colony formation is attributable to molecularly cloned strain of feline leukemia virus with unique long terminal repeat. <i>Res. Vet. Sci.<\/i> 78: 151\u2013154.","DOI":"10.1016\/j.rvsc.2004.07.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nagashima, N., Hisasue, M., Higashi, K., Kano, R., Tsujimoto, H. and Hasegawa, A. 2001. Bone marrow colony-forming unit assay in cats with naturally occurring myelodysplastic syndromes. <i>Int. J. Hematol.<\/i> 73: 453\u2013456.","DOI":"10.1007\/BF02994006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Platzbecker, U. 2019. Treatment of MDS. <i>Blood<\/i> 133: 1096\u20131107.","DOI":"10.1182\/blood-2018-10-844696"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Prihirunkit, K., Narkkong, N. A. and Apibal, S. 2008. Acute monoblastic leukemia in a FeLV-positive cat. <i>J. Vet. Sci.<\/i> 9: 109\u2013111.","DOI":"10.4142\/jvs.2008.9.1.109"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sada, E., Abe, Y., Ohba, R., Tachikawa, Y., Nagasawa, E., Shiratsuchi, M. and Takayanagi, R. 2010. Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages. <i>Eur. J. Haematol.<\/i> 85: 538\u2013548.","DOI":"10.1111\/j.1600-0609.2010.01530.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Scott, L. J. 2016. Azacitidine: a review in myelodysplastic syndromes and acute myeloid leukaemia. <i>Drugs<\/i> 76: 889\u2013900.","DOI":"10.1007\/s40265-016-0585-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., Bloomfield, C. D., Moseley, A., Nazha, A., Zhang, Y., Velasco, M. R., Gaur, R., Atallah, E., Attar, E. C., Cook, E. K., Cull, A. H., Rauh, M. J., Appelbaum, F. R. and Erba, H. P. 2017. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117. <i>J. Clin. Oncol.<\/i> 35: 2745\u20132753.","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Shapiro, R. M. and Lazo-Langner, A. 2018. Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. <i>BMC Hematol.<\/i> 18: 3.","DOI":"10.1186\/s12878-017-0094-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shimoda, T., Shiranaga, N., Mashita, T. and Hasegawa, A. 2000. A hematological study on thirteen cats with myelodysplastic syndrome. <i>J. Vet. Med. Sci.<\/i> 62: 59\u201364.","DOI":"10.1292\/jvms.62.59"},{"key":"24","unstructured":"24. Shirani, D., Nassiri, S. M., Aldavood, S. J., Seddigh, H. S. and Fathi, E. 2011. Acute erythroid leukemia with multilineage dysplasia in a cat. <i>Can. Vet. J.<\/i> 52: 389\u2013393."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Weiss, D. J. 2003. New insights into the physiology and treatment of acquired myelodysplastic syndromes and aplastic pancytopenia. <i>Vet. Clin. North Am. Small Anim. Pract.<\/i> 33: 1317\u20131334.","DOI":"10.1016\/S0195-5616(03)00094-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Weeden, A. L., Taylor, K. R., Terrell, S. P., Gallagher, A. E. and Wamsley, H. L. 2016. Suspected myelodysplastic\/myeloproliferative neoplasm in a feline leukemia virus-negative cat. <i>Vet. Clin. Pathol.<\/i> 45: 584\u2013593.","DOI":"10.1111\/vcp.12426"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/84\/1\/84_20-0352\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:57:39Z","timestamp":1715230659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/84\/1\/84_20-0352\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.20-0352","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"20-0352"}}